Plasma visfatin concentrations in hypothyroid patients and its relationship with thyroid autoimmunity and atherosclerosis
Hipotiroid hastalarda plazma visfatin konsantrasyonlarının tiroid otoimmünitesi ve ateroskleroz ile ilişkisi
Bekir Uçan 1 * , Nur Kebapçı 2, Sema Uslu 3, Mehmet Kara 3, Nevbahar Akçar Değirmenci 4, Setenay Öner 5
1 Department of Endocrinology and Metabolism, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
2 Department of Endocrinology and Metabolism, Osmangazi University Medical Faculty, Eskişehir, Turkey
3 Department of Biochemistry, Osmangazi University Medical Faculty, Eskişehir, Turkey
4 Department of Radiology, Osmangazi University Medical Faculty, Eskişehir, Turkey
5 Department of Biostatistics, Osmangazi University Medical Faculty, Eskişehir, Turkey
* Corresponding Author
Ortadogu Tıp Derg, Volume 10, Issue 4, pp. 498-505
https://doi.org/10.21601/ortadogutipdergisi.364345
OPEN ACCESS
Download Full Text (PDF)
Abstract
Aim: Visfatin/pre-B cell enhancement factor stimulates the production of inflammatory cytokines released from adipose tissue such as TNF-α and IL-6, which are shown to be related to the pathogenesis of insulin resistance, diabetes, dyslipidemia, inflammation, autoimmune diseases, and atherosclerosis. Our aim was to evaluate plasma visfatin concentrations in patients with autoimmune hypothyroidism and its relationship with thyroid autoimmunity and atherosclerosis.
Material and Method: Thirty-five patients with newly diagnosed Hashimoto’s thyroiditis (32 women/3 men, mean age 43.8±9.6 years) and 18 healthy controls (17 women/1 men, mean age 43.3±5.2 years) were enrolled in the study. Anthropometric measurements, carotid intima-media thickness (CIMT), serum anti-Tg, anti-TPO, hsCRP, homocysteine, lipo(a), ApoA, ApoB1, β-2 microglobulin, insulin, glucose, visfatin, IL6, TNF-α, oxidized-LDL concentrations, lymphocyte subgroups and lipid profile were investigated both before and after thyroid hormone replacement therapy. Serum visfatin concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
Results: Mean serum visfatin concentrations were similar between autoimmune hypothyroidism group and control group (6.29 ± 1.63 ng/ml to 6.36 ± 1.51 ng/ml, p>0.05) and it was not correlated with thyroid autoimmunity and atherosclerosis markers. Plasma visfatin, oxidized LDL, IL-6, and TNF-α concentrations did not differ statistically between the control group and hypothyroid patients both before and after the therapy. The cardiovascular risk factors for systolic and diastolic blood pressure, HOMA-IR index, triglyceride, Apo B and ApoB/ApoA, homocysteine, β-2 microglobulin, and CIMT were found to be elevated in patients. Ox-LDL, cholesterol, homocysteine, and proteinuria concentrations were positively correlated with anti-Tg concentrations.
Conclusion: Serum visfatin concentrations were not associated with thyroid autoimmunity and atherosclerosis.
Öz
Amaç: Visfatin/pre-B cell enhancement factor; insülin direnci, diyabet, dislipidemi, inflamasyon, otoimmun hastalıklar ve ateroskleroz patogeneziyle ilişkili adipoz dokudan salınan TNF-alfa ve IL-6 gibi inflamatuar sitokinlerin yapımını uyarır. Bu çalışmada amacımız otoimmün hipotiroidizmli hastalarda plazma visfatin düzeyi ve bunun tiroid otoimmünitesi ve ateroskleroz ile ilişkisini değerlendirmektir.
Gereç ve Yöntem: Çalışmamıza 35 yeni tanı almış Hashimoto hipotiroidili olgu (32 kadın/3 erkek, ort. yaş 43.8±9.6) ve 18 sağlıklı kontrol (17 kadın/1 erkek, ort. yaş 43.3±5.2) dahil edildi. Tiroid hormon replasmanı öncesi ve sonrası antropometrik ölçümler, karotid intima-media kalınlığı (KİMK), serum anti-Tg, anti-TPO, hsCRP, homosistein, lipo(a), ApoA, ApoB1, β-2 mikroglobulin, insulin, glukoz, visfatin, IL6, TNF-α, okside-LDL, lenfosit subgrupları ve lipid profile ölçümleri yapıldı. Serum visfatin konsantrasyonları ELİSA yöntemiyle çalışıldı.
Bulgular: Serum visfatin konsantrasyonları otoimmün hipotiroidizm grubu ile kontrol grubu arasında benzerdi (6.29 ± 1.63 ng/ml to 6.36 ± 1.51 ng/ml, p>0.05), tiroid otoimmünitesi ve ateroskleroz belirteçleriyle korelasyonu saptanmadı. Tedavi öncesi ve sonrası hipotiroidi hastalarının plazma visfatin, okside LDL, IL-6 ve TNF-α konsantrasyonları ile sağlıklı kontrol grubu arasında istatiksel farklılık görülmedi. Sistolik ve diyastolik kan basıncı, HOMA-IR, trigliserid, Apo B and ApoB/ApoA, homosistein, β-2 mikroglobulin, KİMK gibi kardiyovasküler risk faktörleri hasta grubunda yüksek olarak bulundu. Okside-LDL, kolesterol, homosistein ve proteinuria konsantrasyonları anti-Tg ile pozitif korele idi.
Sonuç: Serum visfatin konsantrasyonları ile tiroid otoimmünitesi ve ateroskleroz arasında ilişki bulunmadı.
- Pearce EN, Farwell AP, Braverman LE. Thyroiditis. New England J Med 2003; 348: 2646–55.
- Nyirenda MJ, Clark DN, Finlayson AR, et al. Thyroid disease and increased cardiovascular risk. Thyroid 2005; 15:718-24.
- Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2006; 83:10-3.
- Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972–80.
- Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 2012; 32: 229–43.
- Brentano F, Schorr O, Ospelt J, et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis & Rheumatism 2007; 56: 2829–39.
- Chung CP, Long AG, Solusetal JF. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009; 18: 799–806.
- Ismail S, Mohamed SA. Serum concentrations of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity. British J Dermatol 2012; 167: 436–9.
- Cinar N, Gurlek A. Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: an experimental and clinical update. Endocrine Connections 2013; 2: 30–8.
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 :412-9.
- Caixàs A, Tirado R, Vendrell J, Gallart L, Megía A. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 2009; 71: 733-8.
- Özkaya M, Sahin M, Cakal E , et al. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol İnvest 2009; 32: 435-9.
- Han J, Zhang TO, Xiao WH, Chang CQ, Ai H. Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. Chinese Med J 2012; 125: 874–81.
- Sawicka-Gutaj N, Zybek-Kocik A, Klimowicz A, et al. Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies. Int J Endocrinol 2016: 7402469.
- Nyirenda MJ, Clark DN, Finlayson AR, et al. Thyroid disease and increased cardiovascular risk. Thyroid 2005; 15: 718-4.
- Efstathiadou Z, Bitsis S, Milionis HJ, et al. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? Eur J Endocrinol 2001; 145: 705-10.
- Zhong M, Tan HW, Gong HP, Wang SF, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69: 878-8432.
- Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-35.
- Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism 2007;56 :1131-4.
- Liu SW, Qiao SB, Yuan J, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009; 71: 202-7.
- Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-9.
- Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178: 1748–58.
- Han J, Zhang TO, Xiao WH, Chang CQ, Ai H. Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations. Chinese Med J 2012; 125: 874–81.
- Celik I, Akalin S, Erbas T. Serum levels of interleukin 6 and tumor necrosis factor-a in hyperthyroid patients before and after propylthiouracil treatment. Eur J Endocrinol 1995;132: 668–72.
- Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves’ disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000; 143: 197–202.
- Kita T, Kume N, Minami, et al. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci 2001;947: 199-205.
- Berndt J, Kloting N. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54: 2.
- Dogru T, Sonmez A, Tasci I, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired tolerance. Diabetes Res Clin Pract 2007,76: 24-9.
- O’Leary DH, Pollak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002;90:18-21.
- Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 2002;22: 1162-7.
- Covas MI, Esquerda A, García-Rico A, Mahy N. Peripheral blood T-lymphocyte subsets in autoimmune thyroid disease. J Investig Allergol Clin Immunol 1992;2:131-5.
- A. R. Moschen, A.Kaser, B.Enrichetal, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748–58.
Citation
Uçan B, Kebapçı N, Uslu S, Kara M, Akçar Değirmenci N, Öner S. Plasma visfatin concentrations in hypothyroid patients and its relationship with thyroid autoimmunity and atherosclerosis. Ortadogu Tıp Derg. 2018;10(4):498-505.
https://doi.org/10.21601/ortadogutipdergisi.364345Uçan, B., Kebapçı, N., Uslu, S., Kara, M., Akçar Değirmenci, N., & Öner, S. (2018). Plasma visfatin concentrations in hypothyroid patients and its relationship with thyroid autoimmunity and atherosclerosis.
Ortadoğu Tıp Dergisi, 10(4), 498-505.
https://doi.org/10.21601/ortadogutipdergisi.364345Uçan, B., Kebapçı, N., Uslu, S., Kara, M., Akçar Değirmenci, N., and Öner, S. (2018). Plasma visfatin concentrations in hypothyroid patients and its relationship with thyroid autoimmunity and atherosclerosis.
Ortadoğu Tıp Dergisi, 10(4), pp. 498-505.
https://doi.org/10.21601/ortadogutipdergisi.364345Uçan B, Kebapçı N, Uslu S, Kara M, Akçar Değirmenci N, Öner S. Plasma visfatin concentrations in hypothyroid patients and its relationship with thyroid autoimmunity and atherosclerosis.
Ortadogu Tıp Derg. 2018;10(4), 498-505.
https://doi.org/10.21601/ortadogutipdergisi.364345Uçan, Bekir, Nur Kebapçı, Sema Uslu, Mehmet Kara, Nevbahar Akçar Değirmenci, and Setenay Öner. "Plasma visfatin concentrations in hypothyroid patients and its relationship with thyroid autoimmunity and atherosclerosis".
Ortadoğu Tıp Dergisi 2018 10 no. 4 (2018): 498-505.
https://doi.org/10.21601/ortadogutipdergisi.364345Uçan, Bekir et al. "Plasma visfatin concentrations in hypothyroid patients and its relationship with thyroid autoimmunity and atherosclerosis".
Ortadoğu Tıp Dergisi, vol. 10, no. 4, 2018, pp. 498-505.
https://doi.org/10.21601/ortadogutipdergisi.364345